Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

27 February 2020

Hoelang voordat de pillen op zijn?

This article from Liza van Lonkhuyzen of NRC follows the recent coronavirus outbreak and how it can potentially lead to a global antibiotic shortage. The article features findings from the Foundation's white paper on the issues facing the security of antibiotic supply.

Direct links

Read the full article

With China being one of the major countries to supply raw materials for medicines, the article dives into the factors that may interrupt the supply chain in the backdrop of the outbreak. 

Speaking to many exerts in the field, the report also uses research from the Foundation's white paper Shortages, stockouts and scarcity: the issues facing the security of antibiotic supply and the role for pharmaceutical companies. Here, it refers to the recent shortage of Benzathine benzylpenicillin (BGP) used for the treatment of syphilis in around 40 countries.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved